Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces Price Target of $132.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces Price Target of $132.
